AzTrials
AzTrials

Somatic Symptom Disorder (DSM-5)ENCERT-3YFUNCT03982524

CBT Enriched With Emotion Regulation Training for Multiple Somatoform Symptoms (ENCERT) - A 3-year Follow-up

A study testing Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms and Cognitive-behavioral therapy for patients with multiple somatoform symptoms in people with Somatic Symptom Disorder (DSM-5), run by Philipps University Marburg at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate whether 3 years after the end of therapy cognitive-behavioral therapy complemented with strategies from emotion regulation training leads to better improvement in somatic symptoms and comorbid problems in patients with chronic multiple somatoform symptoms than cognitive… Read more about this study

Who is it for?
Ages 18 to 69 years
Conditions the study is for
Somatic Symptom Disorder (DSM-5)
What is being tested?
Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms and Cognitive-behavioral therapy for patients with multiple somatoform symptoms
Could I receive a placebo?
No, everyone receives an active treatment
How many people
255 participants
Where
1 siteGermany
Study dates
1 Apr 2017to 30 Sep 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 69 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • Severe alcohol/drug addiction
  • Acquired brain injuries
  • Psychoses (history of schizophrenia spectrum disorders; bipolar disorders)
  • Primary disorder requesting other treatments (e.g., suicidality)
  • Biomedical etiology of major symptoms (also if detected during treatment course
  • Ongoing psychotherapy
Show all 10Show fewer
  • Continuous or intermittent, high-dosage (on average more than once per 2 weeks) benzodiazepine treatment
  • Continuous antipsychotic treatment
  • Continuous opioid treatment
  • For patients on medication with antidepressants: treatment regime changes during the time between 4 weeks prior to treatment until follow-up

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • Department of Psychology, Philipps University Marburg

    Marburg, Hesse, 35032

Other trials in Germany

About this study

Official title: Enriching Cognitive-Behavioral Therapy With Emotion Regulation Training in Patients With Chronic Multiple Somatoform Symptoms (ENCERT): A 3-Year Follow-up of a Randomized Controlled Trial

The purpose of this study is to evaluate whether 3 years after the end of therapy cognitive-behavioral therapy complemented with strategies from emotion regulation training leads to better improvement in somatic symptoms and comorbid problems in patients with chronic multiple somatoform symptoms than cognitive behavioral therapy alone.

Read the detailed description

Somatic symptoms not caused by a known biomedical condition ("somatoform disorders") are highly prevalent, involve a high risk of chronicity, are one of the major reasons for doctor visits, and are a tremendous burden for health care systems. Despite the economic relevance, research activities are disproportionately low. The only intervention with an evidence grade I is cognitive behavioral therapy (CBT). However, average effect sizes for CBT in somatization syndromes are only moderate (Cohen's d < 0.5), and more powerful interventions are needed.

There is convincing evidence that patients with somatoform disorders have emotion regulation deficits, which are not addressed by current CBT approaches. We conducted a randomized controlled trial in which we compared a conventional CBT for patients with chronic multiple somatoform symptoms with CBT complemented with emotion regulation techniques (ENCERT; see ClinicalTrials.gov ID: NCT01908855). Previous interventional studies have mainly focused on acute effects and rarely include follow-up periods > 2 years after the end of therapy. The primary goal of the proposed project is to investigate whether effects that were demonstrated for both treatments in our previous randomized controlled trial can be maintained until 3 years after the end of therapy.

This study is based on the intention-to-treat (ITT) sample (N=255 patients) of our previous randomized controlled trial (ClinicalTrials.gov ID: NCT01908855). Patients were primarily recruited via referrals by primary care doctors. After a screening phase baseline assessments with different self- and clinician rating scales (see Outcome Measures) followed. Participants who fulfilled the eligibility criteria were randomized to one of the two study arms: cognitive behavioral therapy vs. cognitive-behavioral therapy complemented with emotion regulation strategies. The post assessment took place after the 20th therapy session and at a follow-up at six months after post treatment. In the current project all randomized patients will be reassessed 3 years after the end of therapy.

Different methods were applied to prevent bias and to assure a high quality level of the current study. Data handling, data monitoring and statistical analyses were supervised by the Coordinating Center for Clinical Trials (KKS) of Philipps-University of Marburg; data quality and safety principles were applied. Additionally an independent Data Safety Monitoring Board was nominated. Randomisation occured and was controlled centrally through the randomisation's central office in KKS Marburg. The current study qualifies as a single-blinded trial. Assessment interviews are conducted and analyzed by people blinded to the treatment condition. Treatments in the previous randomized controlled trial were manualized, and therapists received an intense training. Treatment fidelity/integrity were analyzed with rating schemes for an priori defined proportion of randomly selected videotaped treatment sessions. Allowed additional treatments during study inclusion were thoroughly monitored and analyzed.

The sample size calculation was based on the primary outcome variable "somatization severity index" of the Screening of Somatoform Disorders (SOMS-7T). Based on results of the main validation study of SOMS-7T, metaanalytic estimations, and results of a pilot study of the efficacy of ENCERT, the power calculations yield a necessary total sample size of N=194 to detect a clinical relevant difference of 4 points symptom reduction on SOMS-7T between the two treatments with a power of 0.80 and an alpha=.05. With regard to an estimated drop-out rate of 25%, N=255 patients were recruited.

As main efficacy analysis the primary outcome shall be analyzed with linear mixed-effect models according to the ITT principle. Multilevel longitudinal mediation analyses will be conducted in order to test whether the effect of treatment condition on intraindividual changes in somatic symptom severity can be explained by intraindividual changes in emotion regulation skills.

Being tested
Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms, Cognitive-behavioral therapy for patients with multiple somatoform symptoms
Keywords
somatoform symptoms, somatic symptoms, somatoform disorder, somatic symptom disorder, cognitive-behavioral therapy, emotion regulation training, 3-year follow-up
Medical subject headings
Medically Unexplained Symptoms, Somatoform Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptomsBehavioural

    Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)

  • Cognitive-behavioral therapy for patients with multiple somatoform symptomsBehavioural

    Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)

Study groups in NCT03982524
Study groupRoleWhat they receive
CBT complemented with emotion regulation trainingExperimentalENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning nonjudgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
Receives: Behavioral: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms
Cognitive behavior therapy (CBT)Active comparatorThis arm is based on conventional cognitive-behavioral therapy that can be considered the current "treatment of choice", being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction.
Receives: Behavioral: Cognitive-behavioral therapy for patients with multiple somatoform symptoms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in somatic symptom severity (Screening of Somatoform Disorders, SOMS-7T) from pre-assessment to 3-year follow-up

    Assessment of somatic symptom severity during the last 7 days (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

Secondary outcomes (7)
  1. Change in depressive symptoms (Beck Depression Inventory-II, BDI-II) from pre-assessment to 3-year follow-up

    Assessment of depressive symptoms (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

  2. Change in emotion regulation skills (Emotion Regulation Skills Questionnaire, ERSQ) from pre-assessment to 3-year follow-up

    Assessment of emotion regulation skills (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

  3. Change in symptom-focused coping strategies (Pain Coping Questionnaire) from pre-assessment to 3-year follow-up

    Assessment of symptom-focused coping strategies (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

  4. Change in general psychopathological symptoms (Symptom Checklist-90, SCL-90) from pre-assessment to 3-year follow-up

    Assessment of general psychopathological symptoms (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

  5. Change in symptom-caused disability (Pain Disability Index, PDI) from pre-assessment to 3-year follow-up

    Assessment of symptom-caused disability in different areas of life (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

  6. Change in health-related quality of life (EuroQoL-5D, EQ-5D) from pre-assessment to 3-year follow-up

    Assessment of health-related quality of life (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

  7. Change in health anxiety (modified Short Health Anxiety Inventory, mSHAI) from pre-assessment to 3-year follow-up

    Assessment of health anxiety (self-rating)

    Measured: From pre-assessment (admission) to follow-up (42 months after admission)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2019
  2. Study start1 Apr 2017
  3. Primary completion30 Sep 2019
  4. Study completion30 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
255 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03982524
Sponsor's protocol ID
ENCERT-042017
Other IDs
KL 3132/2-4
Acronym
ENCERT-3YFU
Status last verified
Jul 2025
First submitted
8 Jun 2019
Last updated
14 Jul 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data sharing statement Will individual participant data be available (including data dictionaries)? Yes What data in particular will be shared? Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices). What other documents will be available? Study protocol With whom? Researchers who provide a methodologically sound proposal for re-analyses For what types of analyses? For re-analyses if their aim is covered by the purpose described and agreed on in the patient information sheet and informed consent.

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms and Cognitive-behavioral therapy for patients with multiple somatoform symptoms in people with Somatic Symptom Disorder (DSM-5), run by Philipps University Marburg at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in somatic symptom severity (Screening of Somatoform Disorders, SOMS-7T) from pre-assessment to 3-year follow-up (time frame: From pre-assessment (admission) to follow-up (42 months after admission)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in